Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ClearSign Technologies CorpCLIR · Entity 7487 | Director | September 30, 2026 | October 02, 2026 |
| ENDRA Life Sciences Inc.NDRA · Entity 8083 | Director | January 21, 2026 | January 24, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ClearSign Technologies Corp
Report date September 30, 2026 · Filed October 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-Statutory Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $3.55 · Expires 2036-09-29 | Direct | 3,766 |
Reported balance
After 2026-09-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-30 · Grant · Acquired 3,766 · Balance 3,766 F1: As compensation for services as a non-employee director during the quarter ended September 30, 2026, the reporting person was granted non-statutory stock options to purchase 3,766 shares of common stock under the ClearSign Technologies Corporation Amended and Restated 2021 Equity Incentive Plan pursuant to the issuer's non-employee director compensation policy. These non-statutory stock options were immediately vested and exercisable on the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: As compensation for services as a non-employee director during the quarter ended September 30, 2026, the reporting person was granted non-statutory stock options to purchase 3,766 shares of common stock under the ClearSign Technologies Corporation Amended and Restated 2021 Equity Incentive Plan pursuant to the issuer's non-employee director compensation policy. These non-statutory stock options were immediately vested and exercisable on the grant date.
ENDRA Life Sciences Inc.
Report date January 21, 2026 · Filed January 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 65,709 |
Reported balance
After 2026-01-21 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-01-21 · Grant · Acquired 60,324 · Balance 65,709 F1: Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis. The RSUs will vest in full on January 21, 2027. F2: Includes unvested RSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis. The RSUs will vest in full on January 21, 2027.
F2: Includes unvested RSUs.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 30, 2026 Filed Oct 2, 2026 23:01 UTC | ClearSign Technologies Corp CLIR · Entity 7487 | GrantNon-Statutory Stock Options · Derivative | 3,766 | $0.00 Strike: $3.55 | $0.00 |
DisclosureSEC source: 0001104659-26-113417 · tm2626853-4_4seq1.xml · derivative · entry 1 Basenese Lou · CIK 0001809482 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,766 Underlying: Common Stock · 3,766 shares Expires 2036-09-29 F1 · derivative.exercise_date: As compensation for services as a non-employee director during the quarter ended September 30, 2026, the reporting person was granted non-statutory stock options to purchase 3,766 shares of common stock under the ClearSign Technologies Corporation Amended and Restated 2021 Equity Incentive Plan pursuant to the issuer's non-employee director compensation policy. These non-statutory stock options were immediately vested and exercisable on the grant date. Read SEC document |
| June 30, 2026 Filed Jul 2, 2026 23:01 UTC | ClearSign Technologies Corp CLIR · Entity 7487 | GrantNon-Statutory Stock Options · Derivative | 4,595 | $0.00 Strike: $3.67 | $0.00 |
DisclosureSEC source: 0001104659-26-080470 · tm2619589-3_4seq1.xml · derivative · entry 1 Basenese Lou · CIK 0001809482 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,595 Underlying: Common Stock · 4,595 shares Expires 2036-06-29 F1 · derivative.exercise_date: As compensation for services as a non-employee director during the quarter ended June 30, 2026, the reporting person was granted non-statutory stock options to purchase 4,595 shares of common stock under the ClearSign Technologies Corporation Amended and Restated 2021 Equity Incentive Plan pursuant to the issuer's non-employee director compensation policy. These non-statutory stock options were immediately vested and exercisable on the grant date. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 23:02 UTC | ClearSign Technologies Corp CLIR · Entity 7487 | GrantNon-Statutory Stock Options · Derivative | 3,024 | $0.00 Strike: $4.36 | $0.00 |
DisclosureSEC source: 0001104659-26-039311 · tm2610943-3_4seq1.xml · derivative · entry 1 Basenese Lou · CIK 0001809482 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,024 Underlying: Common Stock · 3,024 shares Expires 2036-03-31 F1 · derivative.exercise_date: As compensation for services as a non-employee director during the quarter ended March 31, 2026, the reporting person was granted non-statutory stock options to purchase 3,024 shares of common stock under the ClearSign Technologies Corporation 2021 Equity Incentive Plan pursuant to the issuer's non-employee director compensation policy. These non-statutory stock options were immediately vested and exercisable on the grant date. Read SEC document |
| January 21, 2026 Filed Jan 24, 2026 00:43 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | GrantCommon Stock | 60,324 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-021412 · ownership.xml · nonDerivative · entry 1 Basenese Lou · CIK 0001809482 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,709 F1 · shares: Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis. The RSUs will vest in full on January 21, 2027. F2 · balance_after: Includes unvested RSUs. Read SEC document |
| October 01, 2025 Filed Oct 3, 2025 22:00 UTC | ClearSign Technologies Corp CLIR · Entity 7487 | GrantRestricted Stock Units · Derivative | 24,621 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-096764 · tm2527975-2_4seq1.xml · derivative · entry 1 Basenese Lou · CIK 0001809482 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,266 Underlying: Common Stock · 24,621 shares Expires not disclosed F1 · derivative.exercise_price: As compensation for services as a non-executive director during the quarter ending December 31, 2025, the reporting person was granted restricted stock units ("RSUs") under the ClearSign Technologies Corporation 2021 Equity Incentive Plan and each RSU represents a right to receive one share of common stock or the cash equivalent thereof. F2 · derivative.exercise_date: The RSUs will vest upon the first to occur of: (1) a Change in Control (as defined in the applicable RSU award agreement), (2) the reporting person's Disability (as defined in the applicable RSU award agreement); (3) the reporting person's death; or (4) the reporting person's separation from service. F2 · derivative.expiration_date: The RSUs will vest upon the first to occur of: (1) a Change in Control (as defined in the applicable RSU award agreement), (2) the reporting person's Disability (as defined in the applicable RSU award agreement); (3) the reporting person's death; or (4) the reporting person's separation from service. Read SEC document |
| July 01, 2025 Filed Jul 3, 2025 22:45 UTC | ClearSign Technologies Corp CLIR · Entity 7487 | GrantRestricted Stock Units · Derivative | 34,722 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-065881 · tm2519904-1_4seq1.xml · derivative · entry 1 Basenese Lou · CIK 0001809482 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,645 Underlying: Common Stock · 34,722 shares Expires not disclosed F1 · derivative.exercise_price: As compensation for services as a non-executive director during the quarter ending September 30, 2025, the reporting person was granted restricted stock units ("RSUs") under the ClearSign Technologies Corporation 2021 Equity Incentive Plan and each RSU represents a right to receive one share of common stock or the cash equivalent thereof. F2 · derivative.exercise_date: The RSUs will vest upon the first to occur of: (1) a Change in Control (as defined in the applicable RSU award agreement), (2) the reporting person's Disability (as defined in the applicable RSU award agreement); (3) the reporting person's death; or (4) the reporting person's separation from service. F2 · derivative.expiration_date: The RSUs will vest upon the first to occur of: (1) a Change in Control (as defined in the applicable RSU award agreement), (2) the reporting person's Disability (as defined in the applicable RSU award agreement); (3) the reporting person's death; or (4) the reporting person's separation from service. Read SEC document |
| June 11, 2025 Filed Jul 1, 2025 10:26 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | GrantCommon Stock | 5,384 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-091888 · ownership.xml · nonDerivative · entry 1 Basenese Lou · CIK 0001809482 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,385 F1 · shares: Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis. The RSUs will vest in full on June 11, 2026. Read SEC document |
| May 22, 2025 Filed May 27, 2025 23:06 UTC | ClearSign Technologies Corp CLIR · Entity 7487 | GrantRestricted Stock Units · Derivative | 10,923 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-053133 · tm2516240-3_4seq1.xml · derivative · entry 1 Basenese Lou · CIK 0001809482 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,923 Underlying: Common Stock · 10,923 shares Expires not disclosed F1 · derivative.exercise_price: As compensation for services as a non-executive director during the quarter ending June 30, 2025, on May 22, 2025, the reporting person was granted restricted stock units ("RSUs") under the ClearSign Technologies Corporation 2021 Equity Incentive Plan, pro-rated based on an appointment date of May 22, 2025, and each RSU represents a right to receive one share of common stock or the cash equivalent thereof. F2 · derivative.exercise_date: The RSUs will vest upon the first to occur of: (1) a Change in Control (as defined in the applicable RSU award agreement), (2) the reporting person's Disability (as defined in the applicable RSU award agreement); (3) the reporting person's death; or (4) the reporting person's separation from service. F2 · derivative.expiration_date: The RSUs will vest upon the first to occur of: (1) a Change in Control (as defined in the applicable RSU award agreement), (2) the reporting person's Disability (as defined in the applicable RSU award agreement); (3) the reporting person's death; or (4) the reporting person's separation from service. Read SEC document |
| January 02, 2024 Filed Feb 23, 2024 22:00 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | GrantStock Options · Derivative | 600 | $0.00 Strike: $1.59 | $0.00 |
DisclosureSEC source: 0001209191-24-003899 · doc4.xml · derivative · entry 1 Basenese Lou · CIK 0001809482 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 600 Underlying: Common Stock · 600 shares Expires 2034-01-02 F1 · shares: Represents a stock option award granted on January 2, 2024 pursuant to the Issuer's Non-Employee Director Compensation Policy. F2 · derivative.exercise_date: This stock option award becomes exercisable in three equal annual installments beginning January 2, 2025. Read SEC document |
| January 30, 2023 Filed Feb 2, 2023 01:30 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | GrantStock Options · Derivative | 6,746 | $0.00 Strike: $4.02 | $0.00 |
DisclosureSEC source: 0001209191-23-006052 · doc4.xml · derivative · entry 1 Basenese Lou · CIK 0001809482 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,746 Underlying: Common Stock · 6,746 shares Expires 2033-01-30 F1 · derivative.exercise_date: This stock option grant becomes exercisable in three equal annual installments beginning January 30, 2024. Read SEC document |
| March 28, 2022 Filed Mar 30, 2022 21:15 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | GrantStock Options · Derivative | 74,500 | $0.00 Strike: $0.38 | $0.00 |
DisclosureSEC source: 0001209191-22-021618 · doc4.xml · derivative · entry 1 Basenese Lou · CIK 0001809482 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,500 Underlying: Common Stock · 74,500 shares Expires 2032-03-28 F1 · derivative.exercise_date: This stock option grant becomes exercisable in three equal annual installments beginning March 28, 2023. Read SEC document |
| January 03, 2022 Filed Jan 4, 2022 22:03 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | GrantStock Options · Derivative | 12,000 | $0.00 Strike: $0.74 | $0.00 |
DisclosureSEC source: 0001209191-22-000951 · doc4.xml · derivative · entry 1 Basenese Lou · CIK 0001809482 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2032-01-03 F1 · shares: Represents a stock option award granted on January 3, 2022 pursuant to the Issuer's Non-Employee Director Compensation Policy. Read SEC document |
| August 26, 2021 Filed Aug 27, 2021 20:15 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | SaleCommon Stock | 5,000 | $1.85 | $9,250.00 |
DisclosureSEC source: 0001209191-21-053613 · doc4.xml · nonDerivative · entry 2 Basenese Lou · CIK 0001809482 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,068 Read SEC document |
| August 25, 2021 Filed Aug 27, 2021 20:15 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | SaleCommon Stock | 45,000 | $1.83 | $82,350.00 |
DisclosureSEC source: 0001209191-21-053613 · doc4.xml · nonDerivative · entry 1 Basenese Lou · CIK 0001809482 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,068 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.81 to $1.84, inclusive. The reporting person undertakes to provide to ENDRA Life Sciences Inc., any security holder of ENDRA Life Sciences Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 05, 2021 Filed Apr 7, 2021 20:13 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | GrantStock Options · Derivative | 25,000 | $0.00 Strike: $2.64 | $0.00 |
DisclosureSEC source: 0001209191-21-025853 · doc4.xml · derivative · entry 1 Basenese Lou · CIK 0001809482 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2031-04-05 F1 · derivative.exercise_date: This stock option grant becomes exercisable in three equal annual installments beginning April 5, 2022. Read SEC document |
| January 04, 2021 Filed Mar 25, 2021 21:01 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | GrantStock Options · Derivative | 12,000 | $0.00 Strike: $0.80 | $0.00 |
DisclosureSEC source: 0001209191-21-023042 · doc4.xml · derivative · entry 1 Basenese Lou · CIK 0001809482 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2031-01-04 F1 · shares: Represents a stock option award granted on January 4, 2021 pursuant to the Issuer's Non-Employee Director Compensation Policy. Read SEC document |
| October 22, 2020 Filed Oct 26, 2020 21:14 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $0.73 | $0.00 |
DisclosureSEC source: 0001209191-20-055831 · doc4.xml · derivative · entry 1 Basenese Lou · CIK 0001809482 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2030-10-22 F1 · derivative.exercise_date: This stock option grant becomes exercisable in three equal annual installments beginning on October 22, 2021. Read SEC document |
| May 29, 2020 Filed Jun 1, 2020 10:27 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | PurchaseCommon Stock | 10,000 | $0.90 | $9,000.00 |
DisclosureSEC source: 0001209191-20-033102 · doc4.xml · nonDerivative · entry 1 Basenese Lou · CIK 0001809482 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,068 F1 · balance_after: Includes unvested restricted stock units. Read SEC document |
| May 28, 2020 Filed May 29, 2020 10:48 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | PurchaseCommon Stock | 10,000 | $0.91 | $9,100.00 |
DisclosureSEC source: 0001209191-20-032826 · doc4.xml · nonDerivative · entry 1 Basenese Lou · CIK 0001809482 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,068 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.89 to $0.92, inclusive. The reporting person undertakes to provide to ENDRA Life Sciences Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. F2 · balance_after: Includes unvested restricted stock units. Read SEC document |
| May 27, 2020 Filed May 28, 2020 10:47 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | PurchaseCommon Stock | 10,000 | $0.85 | $8,500.00 |
DisclosureSEC source: 0001209191-20-032502 · doc4.xml · nonDerivative · entry 1 Basenese Lou · CIK 0001809482 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,068 F1 · balance_after: Includes unvested restricted stock units. Read SEC document |
| May 26, 2020 Filed May 27, 2020 11:25 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | PurchaseCommon Stock | 10,000 | $0.82 | $8,200.00 |
DisclosureSEC source: 0001209191-20-032219 · doc4.xml · nonDerivative · entry 1 Basenese Lou · CIK 0001809482 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,068 F1 · balance_after: Includes unvested restricted stock units. Read SEC document |
| May 21, 2020 Filed May 22, 2020 10:17 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | PurchaseCommon Stock | 10,000 | $0.71 | $7,100.00 |
DisclosureSEC source: 0001209191-20-031547 · doc4.xml · nonDerivative · entry 1 Basenese Lou · CIK 0001809482 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,068 F1 · balance_after: Includes unvested restricted stock units. Read SEC document |
| April 09, 2020 Filed Apr 15, 2020 20:41 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $0.70 | $0.00 |
DisclosureSEC source: 0001209191-20-024484 · doc4.xml · derivative · entry 2 Basenese Lou · CIK 0001809482 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2030-04-09 F3 · shares: Represents a stock option award granted on April 9, 2020 pursuant to the Issuer's Non-Employee Director Compensation Policy. F4 · derivative.exercise_date: This stock option grant becomes exercisable in three equal annual installments beginning April 9, 2021. Read SEC document |
| April 09, 2020 Filed Apr 15, 2020 20:41 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | GrantCommon Stock | 41,587 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-024484 · doc4.xml · nonDerivative · entry 1 Basenese Lou · CIK 0001809482 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,587 F1 · shares: Represents restricted stock units granted in lieu of the Reporting Person's cash retainer payable under the Issuer's Non-Employee Director Compensation Policy for the second, third and fourth quarters of 2020. The restricted stock units vest in three equal installments on the last day of each such calendar quarter. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · balance_after: Includes unvested restricted stock units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.